129 filings
Page 3 of 7
8-K
gsi impcpys1y5wk1r
10 Sep 20
Termination of a Material Definitive Agreement
4:02pm
8-K
kkrq5
9 Sep 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
5:26pm
8-K
ekim y152419jokipjt2
9 Sep 20
Intra-Cellular Therapies Announces Positive Topline Results
7:13am
8-K
xqdr5o2y
10 Aug 20
Intra-cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7:52am
8-K
3t3ol2d
29 Jun 20
Intra-Cellular Therapies Announces PositiveTop-line Results fromITI-214 Phase I/II Study in Patients with Heart Failure
9:14am
8-K
x81ey
28 May 20
Departure of Directors or Certain Officers
4:16pm
8-K
4jmazi8oheryg
7 May 20
Intra-cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
7:42am
8-K
6zxqp2gerhk
23 Mar 20
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
7:52am
8-K
uozpwb3ilz hm7f
2 Mar 20
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2019 Financial Results and Provides Corporate Update
7:43am
8-K
et9zoy
8 Jan 20
Entry into a Material Definitive Agreement
5:12pm
8-K
qrj8bxocuvr vu
6 Jan 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:52pm
8-K
7x4u5glcv1146vamb0
23 Dec 19
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
8:15am
8-K
mzq3d43edori081leo
5 Nov 19
Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2019 Financial Results
7:40am
8-K
1lat9xpf 8jvkediit7
10 Sep 19
Intra-Cellular Therapies Provides Lumateperone Regulatory Update
7:39am
8-K
08job2vsg
7 Aug 19
Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2019 Financial Results
8:08am
8-K
mzvo5w1l3oei7u3u9mw
5 Aug 19
Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA
7:37am
8-K
698ptp6bys3w57t9ui
24 Jul 19
Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophrenia
6:07am
8-K
kvdpzr s8q
8 Jul 19
Intra-Cellular Therapies Announces PositiveTop-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression
7:10am
8-K
0p2qigodr3o54meva
26 Jun 19
Submission of Matters to a Vote of Security Holders
4:31pm
8-K
v9xvkdyn7ak3zmz8n4
8 May 19
Intra-cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update
7:35am